sRAGE attenuates angiotensin II-induced cardiomyocyte hypertrophy by inhibiting RAGE-NFκB-NLRP3 activation

Medicine and Dentistry

• Advanced Glycation End Product Receptor 100%
• Angiotensin II 80%
• Cardiomyocyte 60%
• Synapsin II 40%
• Receptor Protein 40%
• Nucleotide Binding Oligomerization Domain Like Receptor 40%
• Mitogen Activated Protein Kinase 3 20%
• Ventricular Hypertrophy 20%
• Left Ventricular Hypertrophy 20%
• Therapeutic Procedure 20%
• In Vitro 10%
• Pathogenesis 10%
• Interleukin 1 10%
• Protein 10%
• Mediator 10%
• Signal Transduction 10%
• Innate Immunity 10%
• Fluorescence Microscopy 10%
• Receptor Expression 10%
• Alternative Complement Pathway C3 C5 Convertase 10%
• Nuclear Factor 10%
• Enzyme Linked Immunosorbent Assay 10%
• Receptor 10%
• Cell Culture 10%
• Secretion (Process) 10%
• Development 10%
• Arteriosclerotic Heart Disease 10%
• Western Blot 10%
• Cells 10%
• Reactive Oxygen Species 10%